Mostra i principali dati dell'item
Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis
| dc.creator | Karampitsakos T., Torrisi S., Antoniou K., Manali E., Korbila I., Papaioannou O., Sampsonas F., Katsaras M., Vasarmidi E., Papakosta D., Domvri K., Fouka E., Organtzis I., Daniil Z., Dimeas I., Kirgou P., Gourgoulianis K.I., Papanikolaou I.C., Markopoulou K., Kounti G., Tsapakidou E., Papadopoulou E., Tatsis K., Gogali A., Kostikas K., Tzilas V., Chrysikos S., Papiris S., Bouros D., Kreuter M., Tzouvelekis A. | en |
| dc.date.accessioned | 2023-01-31T08:31:18Z | |
| dc.date.available | 2023-01-31T08:31:18Z | |
| dc.date.issued | 2021 | |
| dc.identifier | 10.1186/s12931-021-01725-9 | |
| dc.identifier.issn | 14659921 | |
| dc.identifier.uri | http://hdl.handle.net/11615/74410 | |
| dc.description.abstract | Background: Idiopathic Pulmonary Fibrosis (IPF) represents a chronic lung disease with unpredictable course. Methods: We aimed to investigate prognostic performance of complete blood count parameters in IPF. Treatment-naïve patients with IPF were retrospectively enrolled from two independent cohorts (derivation and validation) and split into subgroups (high and low) based on median baseline monocyte count and red cell distribution width (RDW). Results: Overall, 489 patients (derivation cohort: 300, validation cohort: 189) were analyzed. In the derivation cohort, patients with monocyte count ≥ 0.60 K/μL had significantly lower median FVC%pred [75.0, (95% CI 71.3–76.7) vs. 80.9, (95% CI 77.5–83.1), (P = 0.01)] and DLCO%pred [47.5, (95% CI 44.3–52.3) vs. 53.0, (95% CI 48.0–56.7), (P = 0.02)] than patients with monocyte count < 0.60 K/μL. Patients with RDW ≥ 14.1% had significantly lower median FVC%pred [75.5, (95% CI 71.2–79.2) vs. 78.3, (95% CI 76.0–81.0), (P = 0.04)] and DLCO%pred [45.4, (95% CI 43.3–50.5) vs. 53.0, (95% CI 50.8–56.8), (P = 0.008)] than patients with RDW < 14.1%. Cut-off thresholds from the derivation cohort were applied to the validation cohort with similar discriminatory value, as indicated by significant differences in median DLCO%pred between patients with high vs. low monocyte count [37.8, (95% CI 35.5–41.1) vs. 45.5, (95% CI 41.9–49.4), (P < 0.001)] and RDW [37.9, (95% CI 33.4–40.7) vs. 44.4, (95% CI 41.5–48.9), (P < 0.001)]. Patients with high monocyte count and RDW of the validation cohort exhibited a trend towards lower median FVC%pred (P = 0.09) and significantly lower median FVC%pred (P = 0.001), respectively. Kaplan–Meier analysis in the derivation cohort demonstrated higher all-cause mortality in patients with high (≥ 0.60 K/μL) vs. low monocyte count (< 0.60 K/μL) [HR 2.05, (95% CI 1.19–3.53), (P = 0.01)]. Conclusions: Increased monocyte count and RDW may represent negative prognostic biomarkers in patients with IPF. © 2021, The Author(s). | en |
| dc.language.iso | en | en |
| dc.source | Respiratory Research | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105440751&doi=10.1186%2fs12931-021-01725-9&partnerID=40&md5=08d65528bbc9bcfc5e1a4c6f13836d7d | |
| dc.subject | nintedanib | en |
| dc.subject | pirfenidone | en |
| dc.subject | aged | en |
| dc.subject | all cause mortality | en |
| dc.subject | Article | en |
| dc.subject | cohort analysis | en |
| dc.subject | diffusing capacity for carbon monoxide | en |
| dc.subject | disease exacerbation | en |
| dc.subject | female | en |
| dc.subject | fibrosing alveolitis | en |
| dc.subject | forced vital capacity | en |
| dc.subject | human | en |
| dc.subject | Kaplan Meier method | en |
| dc.subject | major clinical study | en |
| dc.subject | male | en |
| dc.subject | monocyte count | en |
| dc.subject | observational study | en |
| dc.subject | oxygen therapy | en |
| dc.subject | prognosis | en |
| dc.subject | red blood cell distribution width | en |
| dc.subject | retrospective study | en |
| dc.subject | risk factor | en |
| dc.subject | blood | en |
| dc.subject | clinical trial | en |
| dc.subject | epidemiology | en |
| dc.subject | erythrocyte | en |
| dc.subject | fibrosing alveolitis | en |
| dc.subject | Greece | en |
| dc.subject | leukocyte count | en |
| dc.subject | lung | en |
| dc.subject | mean corpuscular volume | en |
| dc.subject | monocyte | en |
| dc.subject | mortality | en |
| dc.subject | multicenter study | en |
| dc.subject | pathophysiology | en |
| dc.subject | predictive value | en |
| dc.subject | prognosis | en |
| dc.subject | reproducibility | en |
| dc.subject | vital capacity | en |
| dc.subject | Aged | en |
| dc.subject | Erythrocyte Indices | en |
| dc.subject | Erythrocytes | en |
| dc.subject | Female | en |
| dc.subject | Greece | en |
| dc.subject | Humans | en |
| dc.subject | Idiopathic Pulmonary Fibrosis | en |
| dc.subject | Leukocyte Count | en |
| dc.subject | Lung | en |
| dc.subject | Male | en |
| dc.subject | Monocytes | en |
| dc.subject | Predictive Value of Tests | en |
| dc.subject | Prognosis | en |
| dc.subject | Reproducibility of Results | en |
| dc.subject | Retrospective Studies | en |
| dc.subject | Vital Capacity | en |
| dc.subject | BioMed Central Ltd | en |
| dc.title | Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis | en |
| dc.type | journalArticle | en |
Files in questo item
| Files | Dimensione | Formato | Mostra |
|---|---|---|---|
|
Nessun files in questo item. |
|||